English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

A key challenge in the development of central nervous system drugs is the availability of drug target specific blood‐based biomarkers. As a new approach, we applied cluster‐based pharmacokinetic/pharmacodynamic ( PK / PD ) analysis in brain extracellular fluid (brain  ECF  ) and plasma simultaneously after 0, 0.17, and 0.86 mg/kg of the dopamine D 2/3  agonist quinpirole ( QP ) in rats. We measured 76 biogenic amines in plasma and brain  ECF   after single and 8‐day administration, to be analyzed by cluster‐based  PK / PD  analysis. Multiple concentration‐effect relations were observed with potencies ranging from 0.001–383  nM . Many biomarker responses seem to distribute over the blood‐brain barrier (BBB). Effects were observed for dopamine and glutamate signaling in brain  ECF  , and branched‐chain amino acid metabolism and immune signaling in plasma. Altogether, we showed for the first time how cluster‐based  PK / PD  could describe a systems‐response across plasma and brain, thereby identifying potential blood‐based biomarkers. This concept is envisioned to provide an important connection between drug discovery and early drug development.

Blood‐Based Biomarkers of Quinpirole Pharmacology: Cluster‐Based PK / PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain